As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
|Articles|January 10, 2008
NACDS sends letter on tamper-resistant Rxs to Medicaid directors
NACDS, 90 organizations send letter to state Medicaid directors on tamper-resistant Rxs.
Advertisement
The National Association of Chain Drug Stores has joined with 90 pharmacy and medical organizations to send a letter to state Medicaid directors requesting that additional guidance be provided to prescribers, pharmacists, and patients regarding compliance with the federal statute requiring the use of tamper-resistant prescription pads (TRPPs) under Medicaid.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
Advertisement
Advertisement
Trending on Drug Topics
1
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
2
FDA Approves Onswik Weekly Insulin for Adults With T2D
3
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
4
Study Finds Reduced Cardiovascular Risk With Hormone Therapy Initiation
5